Irreversible, specific JNK (c-Jun N-terminal Kinase) inhibitor (IC 50 s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3) that forms a covalent bond with a conserved cysteine in the ATP-binding site. Suppresses triple-negative breast cancer (TBNC) cell growth in vitro and in vivo through...
Know who made it. See the evidence. Buy through one marketplace.
Irreversible, specific JNK (c-Jun N-terminal Kinase) inhibitor (IC 50 s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3) that forms a covalent bond with a conserved cysteine in the ATP-binding site. Suppresses triple-negative breast cancer (TBNC) cell growth in vitro and in vivo through upregulation of lysosome biogenesis and autophagy. Suppresses inflammation and oxidative stress during LPS‑induced acute lung injury in mice. Alleviates cognitive impairment, neuroinflammation, and NLRP3 inflammasome activation in a rat model of acute respiratory distress syndrome (ARDS)
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
MAPK8 identifies mitogen-activated protein kinase 8 in Homo sapiens (Human). This target record connects NCBI Gene 5599, UniProtKB P45983 and related ABMIUM catalogue products.
